98%
921
2 minutes
20
There are many different inhaler devices and medications on the market for the treatment of asthma and chronic obstructive pulmonary disease, with over 230 drug-delivery system combinations available. However, despite the abundance of effective treatment options, the achieved disease control in clinical practice often remains unsatisfactory. In this context, a key determining factor is the match or mismatch of an inhalation device with the characteristics or needs of an individual patient. Indeed, to date, no ideal device exists that fits all patients, and a personalized approach needs to be considered. Several useful choice-guiding algorithms have been developed in the recent years to improve inhaler-patient matching, but a comprehensive tool that translates the multifactorial complexity of inhalation therapy into a user-friendly algorithm is still lacking. To address this, a multidisciplinary expert panel has developed an evidence-based practical treatment tool that allows a straightforward way of choosing the right inhaler for each patient.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790222 | PMC |
http://dx.doi.org/10.1007/s12325-021-02034-9 | DOI Listing |
BMC Prim Care
September 2025
Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.
Background: Pressurised metered-dose inhalers (pMDIs), often prescribed for the treatment of COPD and asthma have a high global warming potential (GWP) compared to dry powder inhalers (DPIs) and soft-mist inhalers. Despite calls to switch from high to DPIs or soft-mist inhalers, prescriptions of pMDIs have increased in recent years. Understanding healthcare providers' preferences can help develop strategies to promote prescribing low GWP inhalers.
View Article and Find Full Text PDFChin Med J Pulm Crit Care Med
June 2025
Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Severe asthma affects 5-10 % of asthma patients worldwide, imposing a significant burden due to an increased risk of mortality, impaired quality of life, and substantial economic costs. Recent advancements in biologic therapies have transformed asthma management by targeting specific inflammatory pathways, particularly type 2 inflammation. Biologic treatments such as omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab have demonstrated efficacy in reducing exacerbations, improving lung function, and achieving clinical remission in a subset of patients.
View Article and Find Full Text PDFRespir Med
September 2025
Pulmonology Department Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal.
Purpose: Chronic obstructive pulmonary disease (COPD) management involves pharmacologic therapy delivered via inhalers. Choosing the right inhaler can be challenging. The In-Check Dial G16®, designed as a training device, helps clinicians assess inspiratory capacity by simulating inhaler resistance but can be time-consuming.
View Article and Find Full Text PDFMedicine (Baltimore)
July 2025
Department of Emergency, The First People's Hospital of Neijiang, Neijiang, China.
Pulmonary hypertension (PH) patients with acute respiratory failure (ARF) face high morbidity and mortality rates. This study aimed to determine the optimal respiratory support strategy (high-flow nasal cannula [HFNC] vs noninvasive ventilation) across different grades of RV dysfunction severity in these patients. In this retrospective cohort study, we stratified 90 PH patients with ARF into mild, moderate or severe right ventricular (RV) dysfunction subgroups via propensity score matching.
View Article and Find Full Text PDFAdv Ther
September 2025
COPD Foundation, Lexington, KY, USA.
Introduction: Recent data suggest differences in effectiveness of single-inhaler triple therapies (SITTs) for patients with chronic obstructive pulmonary disease (COPD); however, data specifically from patients previously treated with dual bronchodilator therapy are lacking. This real-world comparative effectiveness study assessed patients with COPD treated with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM) who stepped up from dual therapy.
Methods: This retrospective study used healthcare claims from the Komodo Research database to identify patients with COPD and Medicare Fee-for-Service insurance on dual therapy as their most recent treatment in the 90 days pre-index, stepping up to FF/UMEC/VI or BUD/GLY/FORM between January 1, 2016 and December 31, 2023.